These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11499649)

  • 21. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinson's disease.
    Müller T; Riederer P; Grünblatt E
    J Neural Transm (Vienna); 2017 Jun; 124(6):745-748. PubMed ID: 28299453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Churchyard A; Mathias CJ; Boonkongchuen P; Lees AJ
    J Neurol Neurosurg Psychiatry; 1997 Aug; 63(2):228-34. PubMed ID: 9285463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mysterious MAOI hypertensive episodes.
    Linet LS
    J Clin Psychiatry; 1986 Nov; 47(11):563-5. PubMed ID: 3095312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MAO inhibitors: risks, benefits, and lore.
    Wimbiscus M; Kostenko O; Malone D
    Cleve Clin J Med; 2010 Dec; 77(12):859-82. PubMed ID: 21147941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease.
    Caslake R; Macleod A; Ives N; Stowe R; Counsell C
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006661. PubMed ID: 19821381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Community and long-term care management of Parkinson's disease in the elderly: focus on monoamine oxidase type B inhibitors.
    Chen JJ; Fernandez HH
    Drugs Aging; 2007; 24(8):663-80. PubMed ID: 17702535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotection for Parkinson's disease: prospects and promises.
    Olanow CW; Schapira AH; Agid Y
    Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
    [No Abstract]   [Full Text] [Related]  

  • 33. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.
    Tetrud JW; Langston JW
    Science; 1989 Aug; 245(4917):519-22. PubMed ID: 2502843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations.
    Riederer P; Jellinger K; Danielczyk W; Seemann D; Ulm G; Reynolds GP; Birkmayer W; Koppel H
    Adv Neurol; 1983; 37():159-76. PubMed ID: 6407285
    [No Abstract]   [Full Text] [Related]  

  • 35. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
    Schneider E
    J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
    Kondo T; Takubo H; Yokochi F; Okuma Y; Mizuno Y
    No To Shinkei; 2002 Dec; 54(12):1041-8. PubMed ID: 12599519
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
    Marconi S; Zwingers T
    Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Critical role of MAO inhibition in Parkinson's disease.
    Knoll J
    Adv Neurol; 1987; 45():107-10. PubMed ID: 3103382
    [No Abstract]   [Full Text] [Related]  

  • 39. Monoamine oxidase inhibitors and cardiac anesthesia revisited.
    Noorily SH; Hantler CB; Sako EY
    South Med J; 1997 Aug; 90(8):836-8. PubMed ID: 9258314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.
    Richard IH; Kurlan R; Tanner C; Factor S; Hubble J; Suchowersky O; Waters C
    Neurology; 1997 Apr; 48(4):1070-7. PubMed ID: 9109902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.